

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: NEXALIS THERAPEUTICS LTD</b>
<b>ACN: 611 845 820</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Ronald Wise
<b>Date of last notice</b>	23 December 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	INDIRECT
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Sassey Pty Ltd <Sassey A/C> Sassey Pty Ltd <Avago Super Fund A/C>  <i>Dr Wise is a beneficiary of both entities</i>
<b>Date of change</b>	17 February 2026
<b>No. of securities held prior to change</b>	A. 2,606,302 B. 746,736 C. 500,000 D. 56,659
<b>Class</b>	A. Fully paid ordinary shares B. Performance Rights C. Unlisted Options @\$0.12 Exp 7/7/28 D. Unlisted options @\$0.042 Exp 23 Dec 2027
<b>Number acquired</b>	A. 1,400,000 B. 1,087,026 C. Nil D. 700,000
<b>Number disposed</b>	Nil

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	A. Issue price of \$0.025 B. Deemed price of \$0.023 per right C. N/A D. Nil – 1-for-2 free attaching options for new shares subscribed under the Placement
<b>No. of securities held after change</b>	A. 4,006,302 B. 1,833,762 C. 500,000 D. 756,659
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	A. Subscription of Placement Shares approved at the EGM held 29 Jan26 B. Issue of Performance Rights in lieu of Director fees pursuant to shareholder approval at the AGM held 29 May 2025. C. N/A D. 1-for-2 free attaching options approved at the EGM held 29 Jan26

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	NO
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: NEXALIS THERAPEUTICS LTD</b>
<b>ACN: 611 845 820</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Tony Fitzgerald
<b>Date of last notice</b>	8 July 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	17 February 2026
<b>No. of securities held prior to change</b>	A. 503,324 B. 500,000
<b>Class</b>	A. Performance Rights B. Unlisted Options @\$0.12 Exp 7/7/28
<b>Number acquired</b>	A. 1,087,026 B. Nil
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	A. Deemed price of \$0.023 per right B. Nil
<b>No. of securities held after change</b>	A. 1,590,350 B. 500,000

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	A. Issue of Performance Rights in lieu of Director fees pursuant to shareholder approval at the AGM held 29 May 2025. B. N/A
---	---

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	NO
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: NEXALIS THERAPEUTICS LTD</b>
<b>ACN: 611 845 820</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Sean Williams
<b>Date of last notice</b>	23 December 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<p>TG Advisory Pty Ltd &lt;Williams Glenair Family A/C&gt; <i>Mr Williams is a Director of TG Advisory Pty Ltd and a beneficiary of the Williams Glenair Family A/C</i></p> <p>Mr Sean Williams + Mrs Catherine Williams &lt;S &amp; C Williams Super A/C&gt; <i>Mr Williams is a beneficiary of the S &amp; C Williams Super A/C</i></p>
<b>Date of change</b>	17 February 2026
<b>No. of securities held prior to change</b>	<p>A. 983,920 B. 2,000,000 C. 2,000,000 D. 2,000,000 E. 1,074,866 F. 21,389</p>

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	<p>A. Fully paid ordinary shares</p> <p>B. Unlisted options @\$0.20 Exp 14/12/2026</p> <p>C. Unlisted options @\$0.20 Exp 11/07/2026</p> <p>D. Unlisted options @\$0.15 Exp 03/06/2027</p> <p>E. Performance Rights</p> <p>F. Unlisted options @\$0.042 Exp 23 Dec 2027</p>
<b>Number acquired</b>	<p>A. Nil</p> <p>B. Nil</p> <p>C. Nil</p> <p>D. Nil</p> <p>E. 1,851,567</p> <p>F. Nil</p>
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<p>A. N/A</p> <p>B. N/A</p> <p>C. N/A</p> <p>D. N/A</p> <p>E. Deemed price of \$0.023 per right</p> <p>F. N/A</p>
<b>No. of securities held after change</b>	<p>A. 983,920</p> <p>B. 2,000,000</p> <p>C. 2,000,000</p> <p>D. 2,000,000</p> <p>E. 2,926,433</p> <p>F. 21,389</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<p>A. N/A</p> <p>B. N/A</p> <p>C. N/A</p> <p>D. N/A</p> <p>E. Issue of Performance Rights in lieu of Director fees pursuant to shareholder approval at the AGM held 29 May 2025.</p> <p>F. N/A</p>

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	NO
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.